Comment
doi: 10.1158/2159-8290.CD-NB2018-084.
Epub 2018 Jun 28.
Abiraterone-Olaparib Combo Aids Men with mCRPC
- PMID: 29954730
- DOI: 10.1158/2159-8290.CD-NB2018-084
Item in Clipboard
Comment
Abiraterone-Olaparib Combo Aids Men with mCRPC
Cancer Discov.
2018 Aug.
Abstract
Recent findings from a phase II trial suggest that combining the antiandrogen abiraterone and the PARP inhibitor olaparib significantly improves progression-free survival among patients with metastatic castration-resistant prostate cancer, regardless of their homologous recombination repair-mutation status.
©2018 American Association for Cancer Research.
Comment on
-
Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial.Lancet Oncol. 2018 Jul;19(7):975-986. doi: 10.1016/S1470-2045(18)30365-6. Epub 2018 Jun 4. Lancet Oncol. 2018. PMID: 29880291 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
